Ludwig Enterprises Develops Program to Support Ketamine Clinics

Rhea-AI Summary

Ludwig Enterprises, Inc. (OTC PINK:LUDG) has announced a partnership with Drs. Kim Farahay and Jeff Lee to utilize the company's mRNA Inflammatory Index in enhancing Ketamine treatment for patients with Treatment Resistant Depression. The clinic, set to open in southeastern Ohio in 2023, aims to leverage this innovative program to track inflammatory markers, potentially adjusting treatment dosages based on AI analyses. With Ketamine's established efficacy for resistant depression since the early 2000s, this collaboration could represent a significant advancement in the burgeoning ketamine clinic industry.

Positive

• Partnership with leading doctors to enhance treatment options for Treatment Resistant Depression.
• Utilization of innovative technology (mRNA Inflammatory Index) for personalized treatment.
• Opening of a new Ketamine clinic in southeastern Ohio, expanding market presence.

Negative

• None.

SPARKS, NV / ACCESSWIRE / March 7, 2023 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), The Genomics Language Company™ is pleased to announce an agreement with Drs. Kim Farahay and Jeff Lee to provide them with the Company's newly developed program for use of the mRNA Inflammatory Index™ in Ketamine treatment of patients with Treatment Resistant Depression. Drs. Farahay and Lee are finalizing plans to open a Ketamine clinic in southeastern Ohio in 2023.

"Major depressive disorder is one of the leading causes of morbidity and all-cause mortality (including suicide) worldwide," said Dr. Marvin S. Hausman, MD, Chief Medical Officer of Ludwig Enterprises, and creator of the mRNA Inflammatory Index™. "Our mRNA Inflammatory Index could become a reliable and reproducible biomarker guide to patient treatment selection, evaluation of ketamine dosage used and therapeutic response."

Ketamine is a pharmaceutical discovered over 60 years ago originally approved by the FDA as an anesthetic and analgesic. It was first used psychotherapeutically and for post operative pain in 1974. It was added to the WHO's list of Essential Medicines in 1985. Studies in the early 2000s found Ketamine to be effective in fighting depression resistant to other treatments.

"The ketamine clinic industry is growing rapidly," said Dr. Jeff Lee, the clinic's co-founder. "Our partnership with Ludwig - The Genomics Language Company™ will provide artificial intelligence (AI) to track mRNA inflammatory markers in patients with treatment resistant depression who are undergoing Ketamine therapy, which would be a huge breakthrough for the industry. This statistical analytical approach will assist in substantiating the patient's subjective reporting experience and may allow adjustment of treatment dosage."

About Ludwig Enterprises, Inc.

Ludwig Enterprises, Inc. is a healthcare holding company focused on cutting edge mRNA genomic technology, therapeutics and nutraceuticals. Through its subsidiary Precision Genomics it has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and deep machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and potentially prevent chronic illnesses such as diabetes, COPD, heart disease and cancer. NuGenea™, a scientifically formulated nutraceutical, supported by decades of independent research into the anti-inflammatory properties of its compounds, is manufactured by the Ludwig subsidiary mRNAforLife, Inc and it's My RNA for Life™ product line of nutraceuticals.

Advancements in medical technology have awarded us with cutting-edge genomic tools, unheard of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genomic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including, but not limited to heart disease, diabetes, preeclampsia and cancer. This early detection may allow doctors to take steps to diagnose and manage illness before it progresses and causes serious health problems. Ludwig's innovative testing approach is not only practical but also has the potential to save the healthcare industry millions of dollars in costs. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig and its subsidiary Precision Genomics is poised to significantly impact how we think about disease and live longer healthier lives. For more information please visit: http://www.ludwigent.com.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Precision Genomics & Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Ludwig Enterprises, Inc.
Anne Blackstone, CEO
786-235-9026
www.ludwigent.com

SOURCE: Ludwig Enterprises, Inc.

View source version on accesswire.com:
https://www.accesswire.com/742439/Ludwig-Enterprises-Develops-Program-to-Support-Ketamine-Clinics

FAQ

What is Ludwig Enterprises' recent announcement regarding ketamine treatment?

Ludwig Enterprises has partnered with Drs. Farahay and Lee to implement its mRNA Inflammatory Index in ketamine treatment for patients with Treatment Resistant Depression.

Where will the new ketamine clinic associated with Ludwig Enterprises open?

The new ketamine clinic is set to open in southeastern Ohio in 2023.

What is the significance of the mRNA Inflammatory Index in this partnership?

The mRNA Inflammatory Index aims to provide a reliable guide for treatment selection and dosage adjustment in ketamine therapy.

When was ketamine first used for depression treatment?

Ketamine was found to be effective for depression resistant to other treatments in studies conducted in the early 2000s.